Avalo Therapeutics (AVTX) Equity Income (2019 - 2020)

Avalo Therapeutics (AVTX) reported Equity Income of -$1.9 million for Q2 2020, down 126.44% quarter-over-quarter from $7.1 million in Q1 2020.

Avalo Therapeutics (AVTX) Equity Income (2019 - 2020) Analysis & Trends

Avalo Therapeutics has reported Equity Income for 2 years, with the latest figure at -$1.9 million in Q2 2020.

For the quarter ending Q2 2020, Equity Income changed N/A year-over-year to -$1.9 million; the trailing twelve-month figure through Mar 2021 stood at -$1.9 million (down 126.24% YoY), and the FY2020 full-year result was $5.2 million, up 9556.6% from the prior year.
Equity Income for Q2 2020 stood at -$1.9 million, down from $7.1 million in the prior quarter.
The five-year high for Equity Income was $7.1 million in Q1 2020, with the low at -$1.9 million in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Equity Income (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	235,807.00
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Avalo Therapeutics	295.77 Mn	295.77 Mn	-	-

Download Data